Leverage Cutting-Edge Genome Editing Technology to Accelerate Safe, Precise and Regulatory-Compliant Therapies into the Clinic
Welcome to the 5th Annual Genome Editing Therapeutics Summit
2024 EVENT GUIDE
Only 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal paper, Casgevy marks the remarkable first approval of a gene editing therapy, a landmark moment for a still-developing field. Following closely is a growing pipeline of precision genome editing techniques that are beginning to revolutionize the treatment of genetic diseases.
The 5th Genome Editing Therapeutics Summit (formerly CRISPR 2.0) was the industry’s foremost meeting for spearheading the development, application, and delivery of novel gene editing technologies in the therapeutic setting. Data-driven talks, expert panel discussions, and interactive group discussions covered the therapeutic application and drug development challenges of both:
 |
More established technologies, and their associated translational, nonclinical, clinical, and strategic challenges: including novel nucleases, base, prime, and multiplex editing techniques |
|
Ground-breaking precision tools enabling small and large alterations to the genome, including epigenome editing, recombinase and transposon-based technologies, and novel delivery vehicles |
Across three days, industry and academic leaders shared the latest data on the cutting-edge therapies they were progressing through development, tying in the strategies they deployed to ensure their safety, precision, and regulatory compliance.
This was the industry’s only gene editing meeting that prioritized drug development first, with a particular focus on robust safety packages, off-target detection, and nomination strategies; facilitating successful IND filings. Attendees leveraged actionable insights to improve the precision and safety of their technology, unlocked the ability to perform small and large targeted edits, and outlined a streamlined path to the clinic for their lead program.
They joined to be a part of the gene editing revolution.
“The next decade will see the development of gene editing approaches that will have durable impact on rare diseases and diseases that are more commonplace. This summit affords leaders a place to come together for education and information sharing to collectively progress these approaches.”
Jeffrey Cehelsky, Vice President, Development Operations at Intellia Therapeutics
The 2024 Expert Speaker Faculty Included:
Priya Chockalingam
Vice President, Head of Clinical Bioanalytics & Translational Sciences
Beam Therapeutics
Sam Sternberg (VIRTUAL)
Assistant Professor, Department of Biochemistry & Molecular Biophysics
Columbia University
“Having a better understanding and the current state of art in gene editing is important to keep up with a fast-progressing field, and this meeting enables that.”
Gabor Veres, Senior Vice President, Translational Research at Mammoth Biosciences
2024 Partners:
“I am excited to share and learn newer developments in gene editing technologies, novel delivery modalities and related clinical data.”
Priya Chockalingam, VP, Head of Clinical Bioanalytics & Translational Sciences at Beam Therapeutics
Who Attended in 2023?
